Innate Pharma has received a $15 million milestone payment from Bristol-Myers Squibb under its licensing agreement for lirilumab, for the continued exploration of lirilumab in combination with Opdivo (nivolumab).   This milestone payment follows encouraging preliminary results from the cohort of patients with Squamous Cell Cancer of the Head and Neck (SCCHN) of a Phase I/II trial. These interim efficacy results indicate that targeting both pathways with lirilumab and nivolumab respectively may...